Exact Mass: 426.200206
Exact Mass Matches: 426.200206
Found 238 metabolites which its exact mass value is equals to given mass value 426.200206,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Paliperidone
Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drugs therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1]. Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1].
Cariprazine
C21H32Cl2N4O (426.19530419999995)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics Cariprazine is a novel antipsychotic agent candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).
1-[3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4,5,6-tetrahydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one
(2,3-Dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate
C27H26N2O3 (426.19433260000005)
9-Hydroxy-risperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
Iloperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms[1][2].
MEK inhibitor
Ripisartan
Broussoflavan A
2,4,6,3,4-Pentahydroxy-3,5-diprenyldihydrochalcone
(5-methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone
C27H26N2O3 (426.19433260000005)
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
(+)-3,4-(6,6-dimethyldihydropyrano)-4,5-[2-(1-hydroxy-1-methylethyl)-dihydrofurano]-2,3-dihydroxydihydrochalcone|bartericin C
1,8-dihydroxy-3-(3,7-dimethyl-7-methoxyoct-2-enyloxy)-6-methyl xanthone
Hexyl 6-O-(beta-D-glucopyranosyl)-beta-D-glucopyranoside|Hexyl-??-D-glucopyranosyl-(1鈥樏傗垎 6)-??-D-glucopyranoside
1beta-O-((E)-p-methoxycinnamoyl)-6alpha-hydroxypolygodial|1beta-[(E-p-methoxycinnamoyl)oxy]-6alpha-hydroxypolygodial|isodrimanial
1-[3-(6,7-dihydroxy-3,7-dimethyloct-2-enyl)-2,4-dihydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
(2R,3R)-7,4-dihydroxy-6-(3-hydroxy-3-methylbutyl)-8-(3-methylbut-2-en-1-yl)dihydroflavonol
Hexyl beta-sophoroside|Hexyl-??-D-glucopyranosyl-(1鈥樏傗垎 2)-??-D-glucopyranoside
(4-methylpentyl-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside|capsoside B
2,4,6,3,4-Pentahydroxy- 3,5-diprenyldihydrochalcone
2-Methylbutanoic acid 3-[2-(3,4-dimethoxyphenyl)-7-methoxybenzofuran-5-yl]propyl ester
fukanedone E|rel-3(S)-(2-hydroxy-4-methoxybenzoyl)-4(R),5(R)-dimethyl-5-[4-methyl-5-(4-methyl-2-furyl)-3(E)-penten-1-yl]tetrahydro-2-furanone
alpha,3,4,2,4-Pentahydroxy-5,3-diprenyl-alpha,beta-dihydro-trans-chalcone
2-[6-hydroxy-3,7-dimethylocta-2(E),7-dienyl]-2,3,4,4-tetrahydroxydihydrochalcone
Paliperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics CONFIDENCE standard compound; INTERNAL_ID 1568 Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1]. Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1].
8-(2,4-dihydroxy-6-pentylphenoxy)-6-hydroxy-3-pentylisochromen-1-one
Perospirone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent Perospirone (SM-9018 free base) is an orally active antagonist of 5-HT2A receptor (Ki=0.6 nM) and dopamine D2 receptor (Ki=1.4 nM), and also a partial agonist of 5-HT1A receptor (Ki=2.9 nM). Perospirone is an atypical antipsychotic agent and has the potential for schizophrenic disease research[1][2].
Phe Phe Gly Gly
C22H26N4O5 (426.19031060000003)
Phe Gly Gly Phe
C22H26N4O5 (426.19031060000003)
Gly Phe Phe Gly
C22H26N4O5 (426.19031060000003)
Gly Phe Gly Phe
C22H26N4O5 (426.19031060000003)
Gly Gly Phe Phe
C22H26N4O5 (426.19031060000003)
Win 55212-2
C27H26N2O3 (426.19433260000005)
A organic heterotricyclic compound that is 5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indole substituted at position 6 by a 1-naphthylcarbonyl group. D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
Phe Gly Phe Gly
C22H26N4O5 (426.19031060000003)
BIS(N,N,NN-TETRAMETHYL-D-TARTRAMIDEGLYCOLATO)DIBORON
2-acetamido-3-o-benzyl-4,6-o-benzylidene-2-deoxy-beta-d-glucopyranosyl azide
C22H26N4O5 (426.19031060000003)
Ripisartan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
BIS(N,N,NN-TETRAMETHYL-L-TARTRAMIDEGLYCOLATO)DIBORON
Methanesulfonamide, N-(3-(3-((2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl)-6-ethyl-3-azabicyclo(3.1.0)hex-6-yl)phenyl)-
C24H30N2O3S (426.19770300000005)
Methanone, (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo(1,2,3-de)-1,4-benzoxazin-6-yl)-1-naphthalenyl-, (S)-
C27H26N2O3 (426.19433260000005)
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
L-Asparaginyl-L-phenylalanyl-L-phenylalanine
C22H26N4O5 (426.19031060000003)
Iloperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms[1][2].
8-(2,4-Dihydroxy-6-pentylphenoxy)-6-hydroxy-3-pentylisochromen-1-one
(1S,12R,23R)-12-methyl-23-(2-methylbut-3-en-2-yl)-3,11,14,16-tetrazahexacyclo[12.10.0.02,11.04,9.015,23.017,22]tetracosa-2,4,6,8,17,19,21-heptaene-10,13-dione
N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(thiophen-2-ylmethyl)-2-pyrazinecarboxamide
1-[3-(dimethylamino)propyl]-3-(4-fluorophenyl)-1-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]urea
8-methyl-4-oxo-N-[3-(4-propyl-1-piperazinyl)propyl]-5H-thieno[3,2-c]quinoline-2-carboxamide
2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
[(2S,3R)-6-(benzenesulfonyl)-1-(cyclopentylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-2-yl]methanol
C24H30N2O3S (426.19770300000005)
2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
N,N-dimethyl-4-[4-[(1R,5S)-3-[oxo(2-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzamide
[(2S,3S)-6-(benzenesulfonyl)-1-(cyclopentylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-2-yl]methanol
C24H30N2O3S (426.19770300000005)
[(2R,3R)-6-(benzenesulfonyl)-1-(cyclopentylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-2-yl]methanol
C24H30N2O3S (426.19770300000005)
3-(4-hydroxyphenyl)-1-[2,4,6-trihydroxy-3-[(2Z)-3-(hydroxymethyl)-7-methylocta-2,6-dienyl]phenyl]propan-1-one
9-Hydroxy-risperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
Etrumadenant
Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities[1][2].
His-[D-2-ME-Trp]-Ala
C21H26N6O4 (426.20154360000004)
His-[D-2-ME-Trp]-Ala is a fragment of the growth hormone hexarelin.
7,8-diformyl-4a-hydroxy-4,4,8a-trimethyl-2,3,5,8-tetrahydro-1h-naphthalen-1-yl 3-(4-methoxyphenyl)prop-2-enoate
2-(3,3-dimethylbutyl)-1,3,6-trihydroxy-7-methoxy-8-(3-methylbut-2-en-1-yl)xanthen-9-one
2-[(4-methylpentyl)oxy]-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
(1s,5s,10r)-5-(3,4-dihydroxyphenyl)-9-hydroxy-13,13-dimethyl-2-(3-methylbut-2-en-1-yl)-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-2,8-dien-7-one
(1s,4r,10s,11s,15s)-5,5,10,13,15-pentamethyl-6,19,22-trioxahexacyclo[13.7.1.0¹,¹¹.0⁴,¹⁰.0¹³,²¹.0¹⁷,²¹]tricosa-8,16-diene-7,14,18-trione
(1r,4ar,8r,8as)-7,8-diformyl-4a-hydroxy-4,4,8a-trimethyl-2,3,5,8-tetrahydro-1h-naphthalen-1-yl (2e)-3-(4-methoxyphenyl)prop-2-enoate
4-[(1s,3ar,4s,6ar)-4-{3-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}-hexahydrofuro[3,4-c]furan-1-yl]-2-methoxyphenol
(2s,3r)-5-hydroxy-2-(2-hydroxypropan-2-yl)-3-[(3s)-3-(2-hydroxypropan-2-yl)-7-methyl-2,3-dihydro-1,4-benzodioxin-5-yl]-2,3-dihydro-1h-indene-4-carbaldehyde
3-(3-hydroxy-1,4-dioxonaphthalen-2-yl)-2,2-dimethylpropyl 5-(2,3-dimethyloxiran-2-yl)-2-methylpent-2-enoate
(1r,3r,4s,9s,16s,18s,19r,21s)-16-(hydroxymethyl)-13-methoxy-12,20-dimethyl-11,14-dioxo-5-oxa-8,17,20-triazahexacyclo[15.3.1.0³,¹⁹.0⁴,⁸.0⁹,¹⁸.0¹⁰,¹⁵]henicosa-10(15),12-diene-21-carbonitrile
C22H26N4O5 (426.19031060000003)
3-{[(3r,3as,4s)-3-hydroxy-3-[(1s)-1-hydroxy-2-methylpropyl]-1,4-dimethyl-2-oxo-5,6-dihydro-4h-pentalen-3a-yl]methyl}-4-hydroxy-5-methylchromen-2-one
11'-hydroxy-2,2,2',9',12'-pentamethyl-6',15'-dimethylidene-13'-oxaspiro[pyran-3,5'-tetracyclo[7.5.1.0¹,¹¹.0²,⁷]pentadecane]-6,10',14'-trione
2-(hexyloxy)-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
(2r,3r,4s,5s,6r)-2-[(4-methylpentyl)oxy]-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
1,8-dihydroxy-3-[(7-methoxy-3,7-dimethyloct-2-en-1-yl)oxy]-6-methylxanthen-9-one
1-{3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-2,4,5,6-tetrahydroxyphenyl}-3-(4-hydroxyphenyl)propan-1-one
(2r,3r,5s)-3-hydroxy-5-[(1e,3e,5e,7e,9e,11e,15e)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaen-1-yl]oxolane-2-carboxylic acid
(2r,3s)-2-{3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-4,5-dihydroxyphenyl}-3,4-dihydro-2h-1-benzopyran-3,5,7-triol
(1r,4as,5s,8r,8as)-7,8-diformyl-5-hydroxy-4,4,8a-trimethyl-1,2,3,4a,5,8-hexahydronaphthalen-1-yl (2e)-3-(4-methoxyphenyl)prop-2-enoate
5-(3,4-dihydroxyphenyl)-9-hydroxy-13,13-dimethyl-2-(3-methylbut-2-en-1-yl)-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-2,8-dien-7-one
1-(3,3-dimethylbutyl)-3,6,8-trihydroxy-2-methoxy-7-(3-methylbut-2-en-1-yl)xanthen-9-one
3-(3-hydroxy-1,4-dioxonaphthalen-2-yl)-2,2-dimethylpropyl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate
3-(3-hydroxy-1,4-dioxonaphthalen-2-yl)-2,2-dimethylpropyl (2e,7r)-7-hydroxy-2-methyl-6-methylideneoct-2-enoate
(1s,12r,15s,23r)-12-methyl-23-(2-methylbut-3-en-2-yl)-3,11,14,16-tetraazahexacyclo[12.10.0.0²,¹¹.0⁴,⁹.0¹⁵,²³.0¹⁷,²²]tetracosa-2,4,6,8,17,19,21-heptaene-10,13-dione
3-[2-(3,4-dimethoxyphenyl)-7-methoxy-1-benzofuran-5-yl]propyl (2r)-2-methylbutanoate
(11r)-2-methyl-11-(morpholin-4-ylmethyl)-3-(naphthalene-1-carbonyl)-9-oxa-1-azatricyclo[6.3.1.0⁴,¹²]dodeca-2,4,6,8(12)-tetraene
C27H26N2O3 (426.19433260000005)
(4s,4ar,5r,6s)-3,4a,5-trimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-9-oxo-4h,5h,6h,7h-naphtho[2,3-b]furan-4-yl (2z)-2-methylbut-2-enoate
(1s,6r,14r,15s,17r,22s)-10,15-dihydroxy-6,14,18,18,22-pentamethyl-7,13-dioxapentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁷,²²]docosa-3,9,11,20-tetraene-8,19-dione
3-(3-hydroxy-1,4-dioxonaphthalen-2-yl)-2,2-dimethylpropyl (2e)-5-[(2r,3s)-2,3-dimethyloxiran-2-yl]-2-methylpent-2-enoate
(1'r,2'r,3s,9's,11's,12's)-11'-hydroxy-2,2,2',6',9',12'-hexamethyl-15'-methylidene-13'-oxaspiro[pyran-3,5'-tetracyclo[7.5.1.0¹,¹¹.0²,⁷]pentadecan]-6'-ene-6,10',14'-trione
5,5,10,13,15-pentamethyl-6,19,22-trioxahexacyclo[13.7.1.0¹,¹¹.0⁴,¹⁰.0¹³,²¹.0¹⁷,²¹]tricosa-8,16-diene-7,14,18-trione
(3s)-3-(2,2-dimethyl-3,4-dihydro-1-benzopyran-6-yl)-3-hydroxy-1-[(2s)-6-hydroxy-2-(2-hydroxypropan-2-yl)-2,3-dihydro-1-benzofuran-5-yl]propan-1-one
3-[(1r,4as,7s,7ar)-3-[(2r)-2-hydroxy-3-methylbutanoyl]-4,7-dimethyl-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-1-yl]-4-hydroxy-5-methylchromen-2-one
3-(1-hydroxy-3,4-dioxonaphthalen-2-yl)-2,2-dimethylpropyl (2e)-6-hydroxy-2,6-dimethylocta-2,7-dienoate
3-(2,2-dimethyl-3,4-dihydro-1-benzopyran-6-yl)-3-hydroxy-1-[6-hydroxy-2-(2-hydroxypropan-2-yl)-2,3-dihydro-1-benzofuran-5-yl]propan-1-one
2-methoxy-4-(4-{3-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}-hexahydrofuro[3,4-c]furan-1-yl)phenol
5'-ethenyl-2'-(4-hydroxy-6-methyl-3-oxohept-5-en-2-yl)-7-methoxy-5'-methylspiro[1-benzopyran-3,1'-cyclopentane]-2,4-dione
13-(2-hydroxy-3-methylbutanoyl)-9,14,18-trimethyl-4,12,20-trioxapentacyclo[11.6.1.0²,¹¹.0⁵,¹⁰.0¹⁵,¹⁹]icosa-2(11),5,7,9-tetraen-3-one
(1s,13s,14r,15s,18s,19r)-13-[(2r)-2-hydroxy-3-methylbutanoyl]-9,14,18-trimethyl-4,12,20-trioxapentacyclo[11.6.1.0²,¹¹.0⁵,¹⁰.0¹⁵,¹⁹]icosa-2(11),5,7,9-tetraen-3-one
(2r)-5,7-dihydroxy-8-[(2r)-5-hydroxy-5-methyl-2-(prop-1-en-2-yl)hexyl]-2-(2-hydroxyphenyl)-2,3-dihydro-1-benzopyran-4-one
3-(1-hydroxy-3,4-dioxonaphthalen-2-yl)-2,2-dimethylpropyl (2e)-7-hydroxy-2-methyl-6-methylideneoct-2-enoate
11'-hydroxy-2,2,2',6',9',12'-hexamethyl-15'-methylidene-13'-oxaspiro[pyran-3,5'-tetracyclo[7.5.1.0¹,¹¹.0²,⁷]pentadecan]-6'-ene-6,10',14'-trione
4-hydroxy-3-[3-(2-hydroxy-3-methylbutanoyl)-4,7-dimethyl-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-1-yl]-5-methylchromen-2-one
(1s,12r,23r)-12-methyl-23-(2-methylbut-3-en-2-yl)-3,11,14,16-tetraazahexacyclo[12.10.0.0²,¹¹.0⁴,⁹.0¹⁵,²³.0¹⁷,²²]tetracosa-2,4,6,8,17,19,21-heptaene-10,13-dione
1,8-dihydroxy-3-{[(2e)-7-methoxy-3,7-dimethyloct-2-en-1-yl]oxy}-6-methylxanthen-9-one
(2e)-1-{3-[(2e,6s)-6,7-dihydroxy-3,7-dimethyloct-2-en-1-yl]-2,4-dihydroxyphenyl}-3-(4-hydroxyphenyl)prop-2-en-1-one
(2r,3r)-5-hydroxy-2-(2-hydroxypropan-2-yl)-3-[(3s)-3-(2-hydroxypropan-2-yl)-7-methyl-2,3-dihydro-1,4-benzodioxin-5-yl]-2,3-dihydro-1h-indene-4-carbaldehyde
[(1s,3s,6s,7s,8r,9s)-7-hydroxy-6-[(4-methoxyphenyl)methyl]-3-(methylamino)-5-azatricyclo[6.3.1.0¹,⁵]dodecan-9-yl]oxyphosphonic acid
15-hydroxy-12,16,16-trimethyl-8-(penta-1,3-dien-1-yl)-3,9,11-trioxapentacyclo[10.7.1.0¹,¹⁵.0⁴,²⁰.0⁵,¹⁰]icosa-5(10),7-diene-6,17-dione
3-(3-hydroxy-1,4-dioxonaphthalen-2-yl)-2,2-dimethylpropyl (2e)-5-[(2s,3r)-2,3-dimethyloxiran-2-yl]-2-methylpent-2-enoate
3-{3,4-dihydroxy-2-[(2e,6r)-6-hydroxy-3,7-dimethylocta-2,7-dien-1-yl]phenyl}-1-(2,4-dihydroxyphenyl)propan-1-one
(3r,4s)-6-[(2s)-7-hydroxy-3,4-dihydro-2h-1-benzopyran-2-yl]-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-3,4-dihydro-1-benzopyran-3,4,8-triol
(1'r,2's,3r,7's,9'r,11'r,12's)-11'-hydroxy-2,2,2',9',12'-pentamethyl-6',15'-dimethylidene-13'-oxaspiro[pyran-3,5'-tetracyclo[7.5.1.0¹,¹¹.0²,⁷]pentadecane]-6,10',14'-trione
1,9-diisopropyl-4,6-dimethyl-7,8-dioxooxanthren-2-yl 3-methylbutanoate
6-(7-hydroxy-3,4-dihydro-2h-1-benzopyran-2-yl)-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-3,4-dihydro-1-benzopyran-3,4,8-triol
16-(hydroxymethyl)-13-methoxy-12,20-dimethyl-11,14-dioxo-5-oxa-8,17,20-triazahexacyclo[15.3.1.0³,¹⁹.0⁴,⁸.0⁹,¹⁸.0¹⁰,¹⁵]henicosa-10(15),12-diene-21-carbonitrile
C22H26N4O5 (426.19031060000003)
(1s,3r,4r,9r,16r,18r,19s,21r)-16-(hydroxymethyl)-13-methoxy-12,20-dimethyl-11,14-dioxo-5-oxa-8,17,20-triazahexacyclo[15.3.1.0³,¹⁹.0⁴,⁸.0⁹,¹⁸.0¹⁰,¹⁵]henicosa-10(15),12-diene-21-carbonitrile
C22H26N4O5 (426.19031060000003)